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Enhanced natriuretic response to neutral endopeptidase
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and ANTHONY E.G. RAINE'
Department of Nephrology and Department of Chemical Pathology, St. Bartholomew's Hospital, London, England, United Kingdom
Enhanced natriuretic response to neutral endopeptidase inhibition in
patients with moderate chronic renal failure. Atrial natriuretic factor
(ANF) has natriuretic, renin-suppressing and chronic hypotensive actions
that may be utilized by inhibition of ANF degradation by neutral
endopeptidase, E.C.24.11 (NEP). Three groups of 8 male patients [GFR
103 8 (Normal), 64 6 (Moderate CRF), and 16 2 mI/mm (Severe
CRF)] received 100 mg i.v. bolus of the NEP inhibitor candoxatrilat or
placebo in random order in a double-blind crossover study. GFR (51CR-
EDTA), ERPF (1251-hippuran), ANF (IRMA), urinary cGMP (RIA) and
albumin (RIA) and sodium excretion and flow rate were measured hourly
for two hours before and for seven hours after candoxatrilat administra-
tion. After candoxatrilat plasma ANF rose two- to threefold from baseline,
and remained elevated for 5N and 7M,S hours (P < O.Ol's, P < 0.03M)
associated with an immediate rise in urine cGMP excretion from 235N,
254M and lOA nmol/hr (base) to 517N 73,8M and 27.SS(peak) lasting
7N.M,S hours (P < 0.01NMs). There was a marked natriuresis in all three
groups, the cumulative sodium excretion at seven hours post-candoxatrilat
being lO4, 140M 102S mmol (P < O.05NMs). This was greatest in those
with moderate CRF (moderate CRF vs. normal, P = 0.036, moderate vs.
severe CRF, P = 0.01, normal vs. severe CRF, P = 0.74). Following
candoxatrilat there was a near doubling of the urine flow rate (P < 0.01 N,S,
P < O.02M). Urine albumin excretion increased in patients with renal
failure (P < 0.01), but there was no change in GFR, ERPF or systemic
blood pressure. We conclude that the marked natriuretic effects of acute
NEP inhibition seen in normal subjects are enhanced in the presence of
moderate CRF and sustained even in severe renal impairment.
Administration of low dose atrial natriuretic factor (ANF)
causes natriuresis and diuresis [1], suppression of the renin
angiotensin system [2] and inhibition of sympathetic nerve traffic
[3] in normal subjects. In addition, chronic low dose administra-
tion of ANF in patients with essential hypertension lowers blood
pressure [4]. It has recently become clear that ANF also has
potent growth-inhibitory properties [5]. Long-term elevation of
plasma ANF results in regression of left ventricular hypertrophy
independently of effects on blood pressure [6], and may also
benelicially affect pulmonary vascular remodeling [7]. In patients
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with chronic renal failure, the acute natriuretic response to
exogenous ANF infusion is maintained [8, 9].
To date the therapeutic potential of ANF has been limited by
its short half-life and need for parenteral administration. Orally
active inhibitors of the enzyme responsible for ANF degradation,
neutral endopeptidase (E.C.3.4.24.11), have recently been devel-
oped [10]; their acute administration increases plasma ANF
concentration, resulting in effects analogous to those of ANF in
patients with essential hypertension [11], congestive cardiac fail-
ure [12] and cirrhotic ascites [13]. Their therapeutic effect is
maintained chronically in conditions associated with volume
overload and thus high pre-treatment plasma ANF levels, such as
experimental DOCA/salt hypertension in the rat [14] and clinical
congestive cardiac failure [15]. Furthermore, acute NEP inhibi-
tion with phosphoramidon results in an exaggerated renal excre-
tory and hemodynamic response in experimental renal failure
[16]. The objective of this study was therefore to investigate the
renal response to acute intravenous administration of the neutral
endopeptidase inhibitor, candoxatrilat, in patients with chronic
renal failure. A particular aim was to determine whether NEP
inhibition was capable of inducing a comparable natriuretic effect
in uremic patients to that seen in normal subjects despite the
significant reduction in functional renal mass in uremia, a situa-
tion normally associated with resistance to conventional natri-
uretic agents [17].
METHODS
Patients
Three groups each consisting of eight male patients, defined by
level of renal function, participated in a double-blind, placebo-
controlled, crossover study (Table 1). Each subject was studied on
two occasions separated by at least 10 days, and received either a
100 mg i.v. bolus of the neutral endopeptidase inhibitor candox-
atrilat (Pfizer Central Research, Sandwich, UK) or vehicle (t).9%
saline) on each day. Serum creatinine of patients at screening
was < 120 i.tmol/liler (group 1), 120 to 250 mol/liter (group II),
and > 250 i.tmol/liter (group Ill). All patients had stable renal
function (less than 20% variation in serum crcatinine in the
preceding 3 months). Patients with diabetes mellitus, congestive
cardiac failure, evidence of edema, incomplete bladder emptying
or urinary tract infection were excluded. Antihypertensive drug
therapy was withdrawn for one week prior to each study day. In
order to match sodium intake between study days the patients
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Table 1. Demographic patient details
793
Age
110 57 109
119 30 67
90 31 74
111 36 71
106 55 80.1
81 31 70
93 35 58
82 42 65
130 27 81 115/67
144 61 71 185/106
124 53 71 165/108
104 40 81 135/97
13 185 63 79 125/84
14 148 65 68 153/85
15
16
562 51 58 154/99
568 39 63 129/96
316 39 88 172/100
20 285 60 76 182/84
390 56 61 179/84
322 69 87 173/79
23 662 66 76 137/78
24
CIN
CIN
Renovasc disease
APCKD
Membranous GN
Renovasc disease
CGN
APCKD
Obstruct uropathy
CIN
CIN
Microscopic PAN
CGN
24 Hour
urine
Nat
359 None
92 Nifedipine SR 40
231 Nifedipine SR 80
101 Atenolol 100
Nifedipine SR 20
80 Metoprolol 200
Hydallazine 100
144 Prazosin 2
Nifedipine SR 40
138 Atenolol 50
Nifedipine SR 40
Hydralazine 150
115 Atenolol 25
Nifedipine SR 80
73 Nifedipine SR 20
145 Nifedipine SR 80
166 Atenolol 100
Allopurinol 100
114 Calcichew 3
Nifedipine SR 80
180 Ranitidine 150
286 Prednisolone 10
Calcichew 3
64 Chlorpheniramine 8
Timolol 5
Nifedipine SR 40
93 Allopurinol 100
kept a five-day food diary before the first visit, and the food intake
from this diary was then replicated for the five days before the
second attendance. The experimental protocol was approved by
the District Ethical Committee of St Bartholomew's Hospital. All
patients gave their written informed consent before participating.
Protocol
Patients were studied in the sitting position from 0900 to 1800
hours. All collected 24-hour urine samples prior to each visit and
on the morning of the study had a light, low protein (< 10 g)
breakfast taken with a 500 ml water load. At the start of the study,
the bladder was emptied and two intravenous cannulae inserted,
one for infusion and the other for venous sampling. Cannulae
were kept patent with heparinized saline (10 units per ml). Blood
pressure (oscillometric method; Takeda, Tokyo, Japan) was re-
corded and blood samples for hormonal estimation were taken
each hour just before the patient rose to micturate. In each hour
patients received 300 ml oral water load in addition to 41 ml
normal saline given intravenously to minimize the risk of salt
depletion. Each investigation consisted of a one hour isotope
equilibration, a one hour baseline evaluation followed by either
candoxatrilat or saline infusion over 10 minutes, and then subse-
quent evaluation over seven hours.
Clearance studies
GFR and effective renal plasma flow (ERPF) were calculated
hourly as the clearance of 51Cr-EDTA (50 iCi) and '251-hippuran
(30 iCi), respectively [18]. Each isotope was dissolved in 8 ml of
0.9% saline. One milliliter of this solution was given as an initial
bolus and the remainder diluted in a further 100 ml of saline and
infused at a rate of 11 mI/hr over the next nine hours. Mid-point
plasma samples and aliquots of hourly urine voids were weighed
and counted on a dual channel gamma counter (LKB Multi-
gamma 1261; LKB, Wallac-Oy, Finland) to achieve counts of at
least 10,000 after subtracting the background (< 1% counting
Patient
Sr
iinol/liter
Weight BP"
Kg mm Hg Diagnosis
Group I
2
3
4
5
6
7
8
Group II
9
10
11
12
Drugsc
mg
135/91 Retroperitoneal fibrosis 179 Atenolol 50
126/94 Hypercalciuria 149 Atenolol 50
124/74 MCGN 180 None
128/80 IgA GN 290 None
125/85 Hyperealciuria 103 None
127/71 Hypercalciuria 116 None
120/65 IgA GN 108 None
130/86 APCKD 132 None
Group III
17
18
19
185 60 95 210/119 Hypertensive nephrosclerosis
164 60 85 163/Ill Hypertensive nephrosclerosis
21
22
842 32 105 151/108 FSGS
BP (mm Hg) off drug therapy for 7 days
' Urine sodium, 24-hour urine sodium excretion (mmol) prior to day 1
C Daily dose in mg
Abbreviations are: CGN, chronic glomerulonephritis; APCKD, adult polyeystic kidney disease; CIN, chronic interstitial nephritis; FSGS, focal
segmental glomeruloscierosis; MCGN, minimal change glomerulonephritis.
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error). Correction was made for crossover of 51Cr counts onto 1251
channel (6%).
Blood samples for determination of plasma ANF and plasma
renin concentration (PRC) were collected into chilled 10 ml
polystyrene tubes containing 16 mg of EDTA (potassium salt) and
500 kallikrein inhibitory units of aprotinin. Samples were centri-
fuged immediately, then snap-frozen on dry ice and stored at
—70°C until assayed. Plasma samples taken for determination of
renin concentration (PRC) were stored in the same manner.
Urine aliquots were stored at —20°C until assayed for cyclic GMP
(cGMP), sodium, potassium, creatinine and albumin.
Laboratory techniques
Plasma ANF concentrations were measured in duplicate with a
solid phase two-site immunoradiometric assay not requiring prior
plasma extraction [19]. Urinary albumin concentration [20],
plasma renin concentration [211 and serum aldosterone (Coat a
Count aldosterone; Diagnostic Product Commission, DPC Divi-
sion Euro/DPC Ltd, Caenerfon, Gwynedd, Wales, UK) were
measured by radioimmunoassay. Urine cyclic GMP concentra-
tions were measured by RIA using an antibody provided by Dr. P.
Wood (Regional Endocrine Unit, Southampton General Hospi-
tal, Southampton, UK). Serum and urinary sodium and potassium
concentrations were measured by flame photometer (Instrumen-
tation Labs UK Limited, Warrington, Cheshire, UK). The Beck-
man creatinine analyzer 2 (Beckman Instruments Inc., Fullerton,
CA, USA) was used to measure urinary and serum creatinine
concentrations.
Statistics
Data are expressed as means SEM or as medians with the
range in parentheses in the case of non-parametric data in a
tabular format. For the purpose of clarity results presented
graphically show summary mean or median values. Urinary
albumin excretion has been normalized by logarithmic transfor-
mation. Variables were analyzed for each of the three groups
separately using parametric analysis of variance appropriate for
two-way crossover design [22]. The treatment effect was calculated
both adjusted and unadjusted for period effect. Individual time
point significance compared the value at that time with the
baseline level by the paired t-test. Comparison between groups
used Student's t-test. Correlations were by linear regression or by
Rank Spearman analysis as appropriate.
Statistical significance was taken as P < 0.05.
RESULTS
Clinical details and drug treatment of patients studied are
shown in Table 1. There was no significant difference in any
variable at baseline (Table 2) between neutral endopeptidase and
placebo infusion days in any of the three groups, and no difference
in urine sodium excretion in the 24 hours leading up to each study
day. Baseline, three-hour and seven-hour post-candoxatrilat vari-
ables are shown in Table 3. No side effects were noted on either
the neutral endopeptidase inhibitor or vehicle infusion (lays.
There was no change in any variable in response to vehicle
administration in any of the three groups.
Plasma ANF and urinary cyclic GMP excretion
Baseline plasma ANF concentration was 10.3, 12.1 and 52.7
pmol/l in patients with normal (group I), moderately impaired
Age years
Plasma ANF
pmoi/iiter
UCOMI, V nmoi/
hr
UV mi/hr
UNV jmsoi/
mm
FEN. %
UKV mmoi/hr
BP mm Hg
GFR mi/mini
1.73 m2
ERPF mi/mini
1.73 m2
FF %
Median UAIhV
Jig/mm
Median (range)
plasma renin
jiUlmi
Median serum
aldosterone
ng/di
Heart rate
mm --/
Mean BP mm
Hg
242 (53)
115(32)
333 (43)
143(18)
169 (23)
125(22)
1.0 (0.3)
4.5 (0.9)
120 (5)174 (4)
106 (8.3)
1.8 (0.2)
2.9 (0.4)
154 (12)/97 (6)
64 (6.2)
6.6 (1.8)
2.8 (0.4)
152 (7)/90 (4)
16.4 (2.6)
481 (52) 241 (29) 71(12)
22.6 (1.2)
9(1—32)
27.0 (1.5)
47(7—1436)
23.5 (0.8)
1637 (15—4743)
— 15.0 (2—60)
— 21.6 (12.9—81.6)
60(1.1) 61(2.8) 60(2.9)
94 (4.7) 107 (6.5) 108 (8)
Values are mean (SCM) or median and range.
(group II) and severely impaired renal function (group III),
respectively (Fig. I A, B). There was a highly significant negative
correlation between baseline plasma ANF and GFR (RS =
—0.82, P < 0.0001). Plasma ANF increased significantly from
baseline within one hour of administration of inhibitor, peaked at
around two to three hours, and remained significantly elevated
above baseline for five hours in group 1, and seven hours following
candoxatrilat administration in both groups with chronic renal
failure. Peak plasma ANF was 18.0 pmol/liter in group 1, 30.1
pmol/liter in group II and 147 pmol/liter in group III.
Baseline urinary cyclic GMP excretion was 23.5, 25.4, and 10.4
nmol/hr in the patients with normal GFR, moderate and severe
renal failure, respectively. Urinary cyclic GMP excretion again
increased significantly from baseline in the first hour following
NEP administration peaking at 51.7, 73.8 and 27.5 nmol/hr,
respectively, in the three groups. The time course of the elevation
was similar to the rise in plasma ANF. Urine cGMP excretion
remained significantly elevated above baseline for seven hours
post-drug administration, the incremental rises in all three groups
being two- and threefold from the baseline level.
Natriuresis/diuresis
Baseline sodium excretion in the three groups is given in Table
2. Urinary sodium excretion increased in the first hour after NEP
inhibitor administration in all three groups and peaked at between
2 and three hours in parallel with the changes in plasma ANF
concentration (Fig. 2 A). Excretion remained significantly greater
than baseline levels for seven hours post-dose in patients with
Table 2. Baseline variables of patients with normal GFR, moderately
and severely impaired renal function
Moderate
Normal UJFR CRF Severe CRF
____-
(N=8)
-
8)
40 (4) 54 (5) 52 (5)
10.3 12.1 52.7
23.5 (3.7) 25.4 (3.2) 10.5 (1.4)
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Table 3. Baseline, 3 hour, and 7 hour post-candoxatrilat (100 mg) variables in patients with normal GFR, moderate and severe renal impairment
Urine
Urine Na Mean Median Median Median urine
Plasma eGMP excretion Urine arterial GFR ERPF Filtration plasma plasma albumin
ANF nmol/ iinol/ flow rate pressure mi/mini mi/mini fraction aldosterone renin excretion
pmoi/liter hr mm mi/hr mm Hg 1.73 m2 1.73 m2 % ng/di plUimi p.gimin
Normal GFR
Baseline 10 2 24 4 115 32 242 53 89 4 106 8 481 52 23 1 9(1—32)
3 Hours post-dose 18 4 40 8 231 40 439 33 93 6 100 4 406 25 25 2 13 (2—119)
7 Hours post-dose 12 3 41 9 212 53 382 59 99 7 100 5 427 25 24 1 10 (3—100)
Moderate renal
failure
Baseline 12 1 25 3 143 18 333 43 116 8 64 6 241 29 27 2 47 (7—1436)
3 Hours post-dose 30 4 65 9 332 62 449 33 116 8 64 5 209 15 31 1 210 (7—3602)
7 Hours post-dose 27 5 60 7 276 27 374 24 115 7 64 6 217 17 29 1 154 (10—4509)
Severe renal failure
Baseline 53 10 10 1 125 22 169 23 111 4 16 3 71 12 24 1 22(13—82) 15 (2—60) 163 (15—4743
3Hourspost-dose 147±30 22±3 241 281 116±4 18±3 71 13 27±2 17(10—51) 13(1—45) 1737(17—11189)
7 Hours post-dose 128 28 27 6 180 38 249 27 118 4 17 2 69 12 26 2 20(11—43) 14 (0—45) 2138(17—12124)
normal renal function and moderate renal failure, and for four
hours in those with severe renal impairment. Cumulative urine
sodium excretion following candoxatrilat was greatest in patients
with moderate CRF (140 19), being greater than that seen in
patients with normal GFR (104 23, P = 0.036) or those with
severe CRF (102 20 mmol, P = 0.01). There was no difference
in cumulative sodium excretion following NEP inhibition between
patients with normal GFR and those with severe CRF (P = 0.76)
(Fig. 2B). Subdivision of the severe CRF group into those with the
lowest GFR (GFR 11 1, N = 4) and those with highest GFR
(GFR 23 2, N = 4) demonstrated a similar cumulative rise in
urine sodium (8.2 vs. 10.1-fold, P > 0.05).
Baseline fractional sodium excretion was greater in patients
with chronic renal failure as compared with those with normal
renal function (normal vs. moderate CRF, 0.95 0.3% vs. 1.82
0.2%, P < 0.05; normal vs. severe CRF 1.82 0.2% vs. 6.6 1.8,
P < 0.01; normal vs. severe CRF P < 0.001). Following candox-
atrilat administration, the fractional sodium excretion peaked at
91, 123 and 27% above baseline values in the normal, moderate
and severe CRF groups (P < 0.01, P < 0.01 and P < 0.05,
respectively) within four hours and remained elevated for at least
seven hours post-dose (Fig. 2C).
No correlation was found between percentage change in plasma
ANF and the change in sodium excretion in any of the three
groups. In contrast, cGMP excretion did correlate with the
increase in urine sodium output in patients with chronic renal
failure (RS = 0.4, P < 0.05).
Urine flow rate increased in all three groups following NEP
inhibitor administration (Fig. 3). The incremental rise in water
excretion tended to be higher in subjects with normal renal
function than in patients with chronic renal failure. Urine flow
rates increased from baseline values of 242, 332 and 169 ml/hr to
peak after two hours at 488, 451 and 286 ml/hr in patients with
normal renal function, moderate renal impairment and severe
renal impairment, respectively.
Systemic and renal hemodynamics
Baseline GFR, effective renal plasma flow and derived filtration
fraction are shown in Table 2. GFR tended to be higher, although
not significantly so, in all three groups after candoxatrilat (Fig. 4).
There was also no change in the effective renal plasma flow in
response to NEP inhibition. However, filtration fraction showed a
tendency to increase in all three groups, between 3 and 5% from
baseline.
Baseline mean arterial blood pressure was higher in patients
with renal impairment (P < 0.01) and did not change in the seven
hours following NEP inhibition. There was a nonsignificant trend
to higher mean arterial BP following candoxatrilat in the normal
GFR and severe CRF groups.
Urine albumin excretion
Median urinaly albumin excretion at baseline was8.8, 46.5, and
1637 g/min in patients with normal GFR, moderate renal
impairment and severe renal impairment, respectively (Fig. 5).
There was no significant change in response to NEP inhibition in
patients with normal renal function. In contrast, patients with
renal impairment demonstrated a marked increase in urine
albumin excretion on the actively-treated day (moderate CRF,
P <0.01; severe CRF,P <0.01). This effect was not transient and
continued for the full seven-hour period of observation. The
percentage increase in urinary albumin excretion in the uremic
patients was positively correlated with the rise in the urinary cyclic
GMP excretion (RS = 0.53, P = 0.05) and even more closely
related to urine sodium excretion (RS = 0.70, P < 0.01), but not
to the change in plasma ANF, urine flow rate or change in
filtration fraction.
Plasma renin concentration and serum aldosterone
Median plasma renin concentration and serum aldosterone are
shown at baseline and at four hours and 6.5 hours after candox-
atrilat administration in the group with severe renal impairment
(Table 3). There was no change in either variable.
DISCUSSION
The present study demonstrates that both patients with normal
GFR and those with moderate and severe renal impairment show
a marked renal response to acute neutral endopeptidase inhibi-
tion. Intravenous candoxatrilat infusion resulted in a two- to
threefold rise in plasma ANF and urinary cyclic GMP excretion in
association with a marked natriuresis and moderate diuresis in all
three groups. In patients with severe renal impairment, these
effects were associated with a considerable rise in urinary albumin
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excretion, but with no concomitant activation of the renin-
angiotensin system.
In normal subjects and patients with chronic renal failure, the
effects of exogenous ANF administration are dose-dependent.
Low dose infusion induces moderate natriuresis/diuresis [1, 8],
suppression of the renin-angiotensin system [2] and sympathetic
nerve traffic [3] in association with minor glomerular hemody-
namic change [2, 8]. Larger doses also increase the glomerular
filtration rate [23, 24], and chronic low dose infusion produces a
progressive and sustained antihypertensive effect [4].
Several of the actions of ANF may be relevant to the treatment
of the hypertension and fluid overload that occur in renal
impairment. To date, however, this therapeutic potential has been
limited by the need for parenteral administration of ANF and its
short half-life [25]. Atrial natriuretic factor degradation involves
two separate processes: (a) binding to biologically silent clearance
(C) receptors with subsequent endocytosis [26] and (b) degrada-
tion by the enzyme neutral endopeptidase (NEP), EC.3.4.24.11, a
metallo-endopeptidase widely distributed through the body and
present in large amounts in the proximal tubular brush border of
the kidney [27]. Recently, competitive inhibitors of this enzyme
have been developed and shown to increase endogenous levels of
plasma ANF when administered acutely, in association with
increases in plasma and urinary cyclic GMP, sodium excretion and
reduction in plasma renin activity in normal volunteers [12, 28],
patients with essential hypertension [11], cirrhotic patients with
ascites [13] and patients with congestive cardiac failure [12].
In the present study, the baseline plasma ANF concentration
was elevated in patients with chronic renal failure and was
negatively correlated with pre-treatment glomerular filtration
rate, consistent with previous studies in uremic patients in which
increased ANF level has been related to volume overload, dimin-
ished renal clearance and possibly occult cardiac dysfunction [29].
The sustained rise in plasma ANF following neutral endopepti-
dase inhibition in patients with renal impairment suggests that the
contribution of neutral endopeptidase to ANF degradation re-
mains important despite high ANF levels and diminished renal
mass. In accordance with this theory, Chiu et a! [30] demonstrated
an increase in plasma ANF following neutral endopeptidase
inhibition in bilaterally nephrectomized rats. Furthermore, the
absolute and percentage increases in plasma ANF level following
inhibitor administration were greater in the uremic patients than
those with normal renal function. The implication is that, in this
setting, NEP may become a relatively more important route of
ANF degradation than clearance by C-receptor binding. In accord
with this plasma NEP activity is increased in patients with CRF
[31]. It is well recognized that in conditions associated with high
ANF levels, such as congestive cardiac failure [32] and chronic
high salt intake [33], there is a down-regulation of total ANF
receptors. This is achieved by a reduction in C-receptor numbers
—0.5 0.5 1.5 2.5 3.5 4.5 5.5 6.5
Time, hours
Fig. 3. Urine flow rate response to 100 mg i.v. bolus candoxatrilat (closed
symbols) or vehicle (open symbols) in the three groups of 8 male patients
with (A) normal GFR (circles), moderate (squares) and (B) severe
(triangles) chronic renal failure. In A, P = 0.003 for normal, P 0.011 for
moderate CRF. In B, P = 0.003.
only while the biologically-active receptor density remains con-
stant [34].
Changes in urinary excretion of cyclic GMP, the intracellular
second messenger of ANF, accompanied the changes in plasma
ANF in all three groups. Urinary cyclic GMP excretion represents
both systemic and intrarenal effects of ANF [35], and some studies
have indicated that urinary cyclic GMP excretion correlates better
with the natriuretic action of endogenous ANF than plasma atrial
natriuretic factor itself [36]. Similarly, in the present study urinary
cyclic GMP excretion correlated with the natriuresis in response
to candoxatrilat whereas changes in plasma ANF did not, and
thus, in uremia urinary cyclic GMP may be a better marker of end
organ response than plasma ANF concentration.
As renal mass declines, sodium excretion per remaining
Fig. 2. (opposite page and right) Urine sodium excretion, cumulative
urine sodium excretion, and fractional urine sodium excretion response to
100 mg i.v. bolus candoxatrilat (closed symbols) or vehicle (open symbols)
in three groups of 8 male patients with normal GFR (•), moderate (•),
and severe (A) chronic renal failure. mA, P = 0.032 for normal, P = 0.012
for moderate CRF, and P = 0.002 for the severe CRF groups. In B, *p
0.05 moderate CRF vs. normal and moderate CRF vs. severe CRF. In G,
P < 0.01 for normals, moderate CRF and severe CRF.
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Time, hours
—0.5 0.5 1.5 2.5 3.5 4.5 5.5 6.5
Time, hours
Fig. 4. Mean arterial blood pressure, glomerular filtration rate and
ell'ective renal plasma flow response to 100 mg i.v. bolus candoxatrilat
(closed symbols) or vehicle (open symbols) in three groups of 8 male
patients with normal GFR (circles), moderate (squares) and severe
(triangles) chronic renal failure.
—1.5—0.5 0.5 1.5 2.5 3.5 4.5 5.5 6.5
Time, hours
Fig. 5. Urine albumin excretion response to 100 mg i.v. bolus candox-
atrilat (closed symbols) or vehicle (open symbols) in three groups of 8
male patients with normal GFR (circles), moderate (squares) and severe
(triangles) chronic renal failure.
nephron rises to maintain sodium homeostasis [37], an adaption
that may occur at the expense of raised extracellular volume with
consequent hypertension although clinical edema is uncommon in
pre-end stage disease. It is well recognized that patients with
chronic renal failure are resistant to conventional natriuretic
agents [17]. The exaggerated and prolonged natriuresis seen in
our patients with moderate renal impairment and the sustained
natriuresis exhibited by patients with severe renal failure following
NEP administration is therefore of interest. It is consistent with
the effects of phosphoramidon administration to 5/6 nephrecto-
mized rats, where considerably greater natriuresis in the uremic
than the normal rats was observed [16]. The mechanism by which
ANF induces natriuresis when renal function is normal probably
differs according to the dosage used and remains controversial
[38], although there is considerable evidence that an important
part of the natriuretic response to ANF is due to decreased
sodium uptake by inner medullary collecting duct cells. The
increase in fractional sodium excretion noted in all three groups
following NEP inhibition is consistent with this tubular mecha-
nism. it is of interest, however, that the percent increase in FEN
in patients with CRF tends to be lower than the concomitant
increase in absolute urine sodium excretion, an effect particularly
marked in the severe group. This observation taken together with
the trend for increased GFR in these patients following NEP
inhibition imply that the natriuresis in the patients with CRF
following candoxatrilat may be mediated in part by increased
sodium filtration. High dose ANF infusion in CRF increases
GFR, although plasma ANF levels achieved are higher than those
in this study [I• The greater natriuretic response to NEP inhibi-
tion seen in uremic patients may simply reflect the very high
plasma ANF levels achieved in our patients, as has been observed
with low and high dose ANF infusions in patients with renal
failure [8, 9, 23]. The finding in animals that co-administration of
polyclonal ANF antibodies largely abolishes the natriuretic effect
of NEP inhibitors [3I emphasizes the importance of elevation of
plasma ANF in the natriuretic response to NEP inhibition.
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However, recent evidence suggests other mechanisms may also be
involved. NEP inhibition is associated with increased urinary ANF
excretion in hypertensive animals and in normal volunteers [40,
41] as a result of inhibition of neutral endopeptidase in the
proximal tubule. The demonstration by Sonnenberg, Honrath and
Wilson that microperfusion of inner medullary collecting duct
(IMCD) tubules with ANF increases sodium output [42] implies
that the increased levels of ANF reaching the IMCD may have a
local effect, presumably by binding to biologically-active luminal
receptors. Indeed, in animals NEP inhibition has been associated
with a minimal rise in plasma ANF, but considerable natriuresis in
parallel with increased urinary ANF levels [43]. The increase in
cumulative urine sodium excretion following NEP inhibition in
this study was greater in patients with moderate CRF as compared
to patients with normal GFR and those with severe CRF. In
contrast, no difference was seen between the latter group and
those patients with normal GFR. The mechanism underlying this
exaggerated effect in moderate CRF is beyond the scope of this
study. One may speculate that the exaggerated response com-
pared with patients with normal GFR relates to enhanced activa-
tion of tubular ANF receptors consequent upon the higher plasma
ANF achieved and enhanced intraluminal tubular ANFconcen-
trations that would be expected following proximal tubular NEP
inhibition in patients with moderate CRF (a 4-fold greater
concentration would be expected). This would be supported by
greater urine cGMP excretion in the latter group. Despite con-
siderably higher plasma ANF, the natriuretic response following
NEP inhibition is impaired in the severe CRF in comparison with
the moderate CRF group. This implies that reduced functional
reserve mediates natriuresis by the natriuretic pathway in those
patients with severely diseased kidneys who already exhibit con-
siderable inhibition of sodium reabsorption: witness the FENa+6.6
versus 1.8%. The lower urine cGMP increment in that group
would be in keeping with this speculation.
Prolonged or enhanced plasma candoxatrilat concentrations
consequent upon reduced renal clearance could be relevant to the
enhanced natriuresis seen in the patients with moderate CRF.
Little information exists on its pharmacokinetics in CRF. In a
single dose study in normal and 5/6 nephrectomized rats, there
was no difference in the 24-hour post-dose NEP inhibitor concen-
trations (G.W. Lipkin, personal communication).
In vivo, NEP is involved in the degradation of a number of
peptides that may affect natriuresis including human brain natri-
uretic peptide (BNP), kinins and endothelin [44—461. NEP may
have a greater importance than clearance receptors in the degra-
dation of BNP [47] and furthermore, BNP may be a more effective
natriuretic agent than ANF [48]. Recent in vitro studies demon-
strate that ANF and bradykinin synergistically inhibit sodium
transport in the cortical collecting duct [49]. Kinins probably have
autocrine activity within the kidney [50]. By inhibiting urinary
NEP activity, filtered candoxatrilat would be expected to protect
tubular bradykinin [50]. Indeed, the natriuretic potency of NEP
inhibitors is markedly attenuated by co-administration of specific
bradykinin receptor antagonists without affecting their systemic
hypotensive effect [51]. The significance of this remains to be
determined, as the natriuretic effect of exogenous ANF is also
reduced by the same bradykinin antagonists [51].
ANF itself may also have paracrine or autocrine actions.
Messenger RNA for ANF is found in a wide variety of non-cardiac
tissues [52] including the kidney [53], suggesting a further possible
natriuretic mechanism of NEP inhibition.
Hypertension is a major complication of chronic renal disease,
as indicated by significantly higher mean arterial BP in these
patients in this study. There was no significant change in BP in any
of the three groups following NEP inhibition. Elevation of plasma
ANF by infusion to the range seen in this study in patients with
CRF does not acutely lower BP [8] in contrast to the chronic
antihypertensive effect of prolonged low-dose ANF infusion in
essential hypertension. Recent evidence indicates that administra-
tion of the natriuretic peptide receptor antagonist HS-142-1 leads
to an increase in BP rats with reduced renal mass [54]. These
studies suggest a chronic role of ANF in blood pressure control
and imply a potential long-term benefit of NEP inhibition as an
antihypertensive agent in patients with renal hypertension. Nev-
ertheless, NEP is involved in the degradation of the hypertensi-
nogenic peptides endothelin and angiotensin II [45, 55]. The effect
of chronic NEP inhibition on BP in renal hypertension therefore
requires further study.
Urinary albumin excretion rose markedly in patients with renal
impairment but not those with normal renal function in our study.
ANF increases urine protein excretion in patients with primary
glomerular disease [56] and renal transplant recipients [571.
Recent evidence indicates that the albuminuric effect of ANF is
not simply related to increased urine flow rate and hence tubular
washout [58]. ANF increases capillary permeability in the systemic
vasculature [59], an effect which may also occur in glomerular
capillaries. ANF induces preglomerular vasodilation and post-
glomerular vasoconstriction [60], with an associated increase in
intraglomerular capillary pressure that would be predicted to
increase albumin filtration. The finding of increased filtration
fraction in the present study is consistent with this mechanism.
ANF binds to mesangial cells and reduces angiotensin Il-medi-
ated contraction [611, thus increasing glomerular filtration area,
with the potential for further loss of albumin. The marked
increase in urine albumin excretion seen in this study in patients
with CRF following NEP inhibition would be of potential concern
if this were maintained in chronic studies in humans. Increased
proteinuria is associated with elevated rate of progression of CRF
[62]. Further studies are required to address this problem.
In this study, despite a considerable increase in sodium excre-
tion, candoxatrilat treatment was not associated with activation of
the renin-angiotensin system. ANF administration results in sup-
pression of renin and aldosterone release in normal subjects [1],
and this effect is mimicked by NEP inhibition in normal subjects
and patients with cardiac failure [12]. The contribution of these
changes in the renin-angiotensin system (RAS) to the natriuresis
following NEP inhibition is unknown. Significant natriuretic and
antihypertensive effects have been documented with NEP inhibi-
tion in black subjects with low renin essential hypertension,
suggesting that RAS blockade does not make a major contribu-
tion [63]. Nevertheless, it is of note that in the present study,
marked natriuresis occurred in patients with severe CRF without
activation of the RAS, in contrast to the increase in plasma renin
activity which is seen with conventional diuretic therapy.
The lack of concomitant activation of the RAS during NEP
inhibitor administration may be of potential therapeutic impor-
tance, if it persists during chronic treatment. Although significant
long-term antihypertensive benefit has not been demonstrated
with NEP inhibition in the spontaneously hypertensive rat and in
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patients with essential hypertension [6, 64], uncomplicated hyper-
tension is associated with relatively low basal plasma ANF con-
centrations. In contrast, in conditions associated with high pre-
treatment ANF concentrations such as experimental DOCA/salt
hypertension in rats and clinical congestive cardiac failure, sus-
tained natriuretic and hemodynamic effects have been observed in
response to NEP inhibition [14, 15]. The same may apply to
chronic renal failure. The recent finding that the chronic antihy-
pertensive effect of candoxatril may be limited by reduction in
angiotensin II metabolism [551 implies that the combination of
NEP and converting enzyme inhibition may be a fruitful thera-
peutic approach. Indeed, combination of these modes of therapy
tools to enhanced efficacy in models of hypertensive heart failure
[65, 66].
In keeping with the present findings, a recent study examined
the effect of acute NEP inhibition with sinorphan in patients with
renal impairment, and demonstrated a twofold rise in urine
sodium excretion [671. While interesting, evaluation of this study
is to some extent limited by the use of creatinine clearance as a
matter of GFR and by the failure to withdraw antihypertensive
medication before study. This study also lacks a normal renal
function control group, although corresponding data have been
published by the same group in a previous report [281.
In conclusion, acute NEP administration is associated with
marked natriuresis in patients with normal GFR. The natriuresis
is enhanced in moderate chronic renal failure and sustained even
in severe renal impairment, and occurs without an associated
activation of the renin-aldosterone system. The potential role of
this therapeutic approach in the hypertension and fluid overload
associated with renal impairment merits further investigation.
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